Hepatitis C is a Major Global Public Health Problem!
Call for abstracts:
HCV Community Summit
18-19 April in Amsterdam
Eradication of hepatitis C asks for Community Involvement
With the new medicines now available an opportunity exists to completely eradicate
hepatitis C. However, it will require pharmaceutical companies, governments, doctors,
and health purchasers to come together to ensure these medicines are quickly available
to all. Also a crucial factor for success will be the involvement of people living with
hepatitis C and well-resourced harm reduction services.
The summit will bring together experts and representatives to discuss the needs, gaps
and opportunities to make treatment available for all people in need. Also to present
community approaches for testing and treatment for HCV (and B) and to discuss/agree
on further community action and advocacy.
The summit will also reach out to attendees of the International Lever Congress, organised by EASL at the same time.
Please consult www.hepatitiscommunitysummit.eu
for abstract submission and registration.
Hepatitis B and C testing: Why? Who? How?
A guidance paper on testing in community and harm reduction settings
This paper aims to stimulate services to engage in HCV and HBV awareness raising and in particular to inform community members, social and health care practitioners about current HBV/HCV testing and diagnosis methods, screening technologies and other aspects around the issue.
The aims of the Correlation Berlin Hepatitis C Manifesto:
Did dreams come true?
Access to prevention, testing, treatment and care for people who use drugs
Eberhard Schatz, Katrin Schiffer, Mags Maher, Magdalena Harris, Xavier Major Roca,
Mojca Maticic and Astrid Leicht
Urgent action to fight hepatitis C in people
who inject drugs in Europe
John F. Dillon, Jeffrey V. Lazarus and Homie A. Razavi
The time to foster a unified global response
to the hepatitis C epidemic is now!
- Develop Targeted HCV Strategies and Action Plans
- Provide Access to HCV Testing, Treatment and Care Services
- Scale-up Harm Reduction, evidence and rights and Community-Based Programs
- Decriminalize People Who Use Drugs
- Meaningful inclusion of People who Inject Drugs and their organisations
- Increase Health and HCV Literacy
Hepatitis C among drug users in Europe:
epidemiology, treatment and prevention
EMCDDA, Lisbon, July 2016
EMCDDA published a new INSIGHT report: epidemiology, treatment and prevention provides a timely contribution to raising awareness of the hepatitis C epidemic in Europe and the opportunities now opening up to tackle this problem decisively. A state of the art review of the epidemiology of hepatitis C virus (HCV) infection in Europe and an overview of the way preventive measures are currently implemented in European countries set the scene. International experts address the treatment of HCV infection among people who inject drugs, with an emphasis on how we encourage uptake and deliver effective outcomes. Implementation issues are also explored, as are the complementary roles of treatment and prevention. The new medicines and treatment regimens driving the transformation in the HCV treatment landscape are reviewed in detail. The challenges of scaling up HCV treatment and successfully involving drug using patients is explored from different viewpoints, including that of the drug user.